He also emphasized the significance such patents have on the company’s success. “This patent award bolsters the technical advantages offered by TRT’s medical devices and furthers TRT’s efforts to achieve cost efficiency and clinical superiority over competing platforms,” Warlick said.
“This patent award bolsters the technical advantages offered by TRT’s medical devices and furthers TRT’s efforts to achieve cost efficiency and clinical superiority over competing platforms.”
Tissue Regeneration Technologies, LLC awarded another patent to expand its SoftWave™ technology portfolio.
WOODSTOCK, GA. -- Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA. based medical technology company, announced Monday it received another patent award to expand its innovative unfocused shock wave technology portfolio.
The company’s newest patent award (U.S. Patent 7,695,443) covers a novel device for generating shock waves. TRT’s patent portfolio increases to 15 granted patents and 20 published patent applications. TRT retains rights to its expanding intellectual property portfolio as an exclusive owner and exclusive licensee.
John Warlick, Chief Executive Officer of TRT, stated the recent patent award is aimed at further increasing the effectiveness and reliability of its SoftWave™– unfocused shock wave– technologies.
Warlick also recognized the reciprocal benefits of private and public research within the shock wave community. “TRT’s clear commitment to technical and clinical researchers and the shock wave community continues to result in tangible growth of our intellectual property portfolio,” he said.
TRT is the industry leader in providing unfocused shock wave technology and is committed to establishing its SoftWave™ technology as the new standard for wound care, cardiology and orthopedics. TRT was founded in 2005 to develop unfocused SoftWave technology in wound care and orthopedics and has since expanded its operations to the urology, cardiology, dental and neurological fields.
Research has shown unfocused shock waves have strong regenerative effects on all avascular (scar) tissues by stimulating strong biologic responses. These include the production of growth factors, nitric oxide, and critical gene expressions, which results in angiogenesis and improve blood supply and antibacterial properties of treated areas. Conditions that benefit from shock wave treatment include acute and chronic wounds, non-healing bones, ischemic heart tissue, prostatitis and burns.
The company is currently involved in U.S. Food and Drug Administration trials for its “Gold” product line, which is approved in Europe, Asia, Canada and South America. TRT is confident its technologies will dramatically improve patient care and reduce health care costs.